pteridines has been researched along with Disease Exacerbation in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 5.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| " Treatment of syngeneic R3T or 4T1 tumor-bearing mice with orally given SD-208 inhibited primary tumor growth as well as the number and size of metastases." | 3.73 | Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. ( Barnard, N; Chakravarty, J; Dugar, S; Ge, R; Lattime, E; Medicherla, S; Murphy, A; Protter, A; Rajeev, V; Ray, P; Reiss, M; Rittling, S; Schreiner, G, 2006) |
| "Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase." | 2.82 | Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study. ( Del Campo, JM; Follana, P; Freyer, G; Garin-Chesa, P; Gladieff, L; Joly, F; Lesoin, A; Lortholary, A; Marzin, K; Nazabadioko, S; Pardo, B; Pilz, K; Pujade-Lauraine, E; Ray-Coquard, IL; Sassi, M; Selle, F; Sufliarsky, J; Tholander, B; Vergote, I; Vidal, L; Weber, B, 2016) |
| " The MTD for the second dosing schedule was not determined; a 225-mg dose was well tolerated." | 2.75 | An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. ( Al-Batran, SE; Fritsch, H; Hochhaus, A; Hofheinz, RD; Jäger, E; Munzert, G; Reichardt, VL; Trommeshauser, D, 2010) |
| "Melanoma is one of the most treatment-resistant malignancies and regardless of new therapeutic tactics the outcome remains dismal." | 1.38 | In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells. ( Brassesco, MS; de Oliveira, JC; Montaldi, AP; Morales, AG; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG; Valera, ET, 2012) |
| "Gliomas are the most devastating of primary adult malignant brain tumors." | 1.38 | Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study. ( Ang, BT; Brooks, HB; Campbell, RM; Chong, YK; Foong, CS; Sandanaraj, E; Tang, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Tian, L | 1 |
| Yao, K | 1 |
| Liu, K | 1 |
| Han, B | 1 |
| Dong, H | 1 |
| Zhao, W | 1 |
| Jiang, W | 1 |
| Qiu, F | 1 |
| Qu, L | 1 |
| Wu, Z | 1 |
| Zhou, B | 1 |
| Zhong, M | 1 |
| Zhao, J | 1 |
| Qiu, X | 1 |
| Zhong, L | 1 |
| Guo, X | 1 |
| Shi, T | 1 |
| Hong, X | 1 |
| Lu, S | 1 |
| Breitenbuecher, F | 1 |
| von Pawel, J | 1 |
| Sebastian, M | 1 |
| Kortsik, C | 1 |
| Ting, S | 1 |
| Kasper, S | 1 |
| Wohlschläger, J | 1 |
| Worm, K | 1 |
| Morresi-Hauf, A | 1 |
| Schad, A | 1 |
| Westerwick, D | 1 |
| Wehler, B | 1 |
| Werner, M | 1 |
| Munzert, G | 2 |
| Gaschler-Markefski, B | 1 |
| Schmid, KW | 1 |
| Schuler, M | 1 |
| Shao, C | 1 |
| Ahmad, N | 1 |
| Hodges, K | 1 |
| Kuang, S | 1 |
| Ratliff, T | 1 |
| Liu, X | 1 |
| Pujade-Lauraine, E | 1 |
| Selle, F | 1 |
| Weber, B | 1 |
| Ray-Coquard, IL | 1 |
| Vergote, I | 1 |
| Sufliarsky, J | 1 |
| Del Campo, JM | 1 |
| Lortholary, A | 1 |
| Lesoin, A | 1 |
| Follana, P | 1 |
| Freyer, G | 1 |
| Pardo, B | 1 |
| Vidal, L | 1 |
| Tholander, B | 1 |
| Gladieff, L | 1 |
| Sassi, M | 1 |
| Garin-Chesa, P | 1 |
| Nazabadioko, S | 1 |
| Marzin, K | 1 |
| Pilz, K | 1 |
| Joly, F | 1 |
| Kaneda, MM | 1 |
| Cappello, P | 1 |
| Nguyen, AV | 1 |
| Ralainirina, N | 1 |
| Hardamon, CR | 1 |
| Foubert, P | 1 |
| Schmid, MC | 1 |
| Sun, P | 1 |
| Mose, E | 1 |
| Bouvet, M | 1 |
| Lowy, AM | 1 |
| Valasek, MA | 1 |
| Sasik, R | 1 |
| Novelli, F | 1 |
| Hirsch, E | 1 |
| Varner, JA | 1 |
| Hofheinz, RD | 1 |
| Al-Batran, SE | 1 |
| Hochhaus, A | 1 |
| Jäger, E | 1 |
| Reichardt, VL | 1 |
| Fritsch, H | 1 |
| Trommeshauser, D | 1 |
| Mohammad, KS | 1 |
| Javelaud, D | 1 |
| Fournier, PG | 1 |
| Niewolna, M | 1 |
| McKenna, CR | 1 |
| Peng, XH | 1 |
| Duong, V | 1 |
| Dunn, LK | 1 |
| Mauviel, A | 1 |
| Guise, TA | 1 |
| Lee, C | 1 |
| Fotovati, A | 1 |
| Triscott, J | 1 |
| Chen, J | 1 |
| Venugopal, C | 1 |
| Singhal, A | 1 |
| Dunham, C | 1 |
| Kerr, JM | 1 |
| Verreault, M | 1 |
| Yip, S | 1 |
| Wakimoto, H | 1 |
| Jones, C | 1 |
| Jayanthan, A | 1 |
| Narendran, A | 1 |
| Singh, SK | 1 |
| Dunn, SE | 1 |
| de Oliveira, JC | 1 |
| Brassesco, MS | 1 |
| Pezuk, JA | 1 |
| Morales, AG | 1 |
| Valera, ET | 1 |
| Montaldi, AP | 1 |
| Sakamoto-Hojo, ET | 1 |
| Scrideli, CA | 1 |
| Tone, LG | 1 |
| Haupenthal, J | 1 |
| Bihrer, V | 1 |
| Korkusuz, H | 1 |
| Kollmar, O | 1 |
| Schmithals, C | 1 |
| Kriener, S | 1 |
| Engels, K | 1 |
| Pleli, T | 1 |
| Benz, A | 1 |
| Canamero, M | 1 |
| Longerich, T | 1 |
| Kronenberger, B | 1 |
| Richter, S | 1 |
| Waidmann, O | 1 |
| Vogl, TJ | 1 |
| Zeuzem, S | 1 |
| Piiper, A | 1 |
| Foong, CS | 1 |
| Sandanaraj, E | 1 |
| Brooks, HB | 1 |
| Campbell, RM | 1 |
| Ang, BT | 1 |
| Chong, YK | 1 |
| Tang, C | 1 |
| Ge, R | 1 |
| Rajeev, V | 1 |
| Ray, P | 1 |
| Lattime, E | 1 |
| Rittling, S | 1 |
| Medicherla, S | 1 |
| Protter, A | 1 |
| Murphy, A | 1 |
| Chakravarty, J | 1 |
| Dugar, S | 1 |
| Schreiner, G | 1 |
| Barnard, N | 1 |
| Reiss, M | 1 |
| Larnaout, A | 1 |
| Belal, S | 1 |
| Miladi, N | 1 |
| Kaabachi, N | 1 |
| Mebazza, A | 1 |
| Dhondt, JL | 1 |
| Hentati, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy[NCT01121406] | Phase 2 | 110 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma[NCT03795610] | Phase 2 | 15 participants (Anticipated) | Interventional | 2020-03-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for BI 6727 BS (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Volasertib | 2140 |
AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for CD 10899 BS (metabolite of Volasertib BI 6727) (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Volasertib | 204 |
AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for BI 6727 BS (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Volasertib | 6240 |
AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for CD 10899 BS (metabolite of Volasertib BI 6727) (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Volasertib | 1400 |
"Biological PFS including assessment of CA-125 levels was defined as the time from randomisation until the first occurrence of progressive disease according to CA-125, progressive disease according to radiological evidence, or death.~Also according to the below criterias,~In patients with radiological measurable disease, disease progression during study treatment could not be declared on the basis of CA-125 alone.~Patients with elevated CA-125 pre-treatment and normalization of CA-125 had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart or~Patients with elevated CA-125 pre-treatment, which never normalized, had to show evidence of CA-125 ≥ to two times the nadir value on two occasions at least one week apart or~Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart." (NCT01121406)
Timeframe: At screening and every 6 weeks thereafter (Up to 213 weeks )
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | 13.1 |
| Cytotoxic | 20.6 |
CL; total clearance of BI 6727 BS in plasma after intravenous administration (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | mL/min (Geometric Mean) |
|---|---|
| Volasertib | 801 |
Cmax; maximum measured concentration of BI 6727 BS in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Volasertib | 341 |
Cmax; maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Volasertib | 10.8 |
DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD). (NCT01121406)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Volasertib (BI 6727) | 30.6 |
| Cytotoxic | 43.1 |
MRT; Mean residence time of BI 6727 BS in the body (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | hours (Geometric Mean) |
|---|---|
| Volasertib | 118 |
OS is defined as time from randomisation to death irrespective of the cause of the death. (NCT01121406)
Timeframe: From randomization until death or study discontinuation; Up to 213 weeks
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | 60.1 |
| Cytotoxic | 68.6 |
"Progression-free survival of a patient was based on the investigator's assessment; it was defined as the number of days from the date of randomisation until the date of either disease progression or death from any cause, whichever occurred first.~Definition of disease progression according to RECIST version 1.1; Patients with measurable tumour lesions at baseline, Target-lesions: at least a 20% increase in the sum of diameters of target lesions, the sum of diameters must also demonstrate an absolute increase of at least 5 mm,taking as reference the smallest sum on study, or appearance of 1 or more new lesions.~Non-target lesions: unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions Patients with non-measurable tumour lesions at baseline, Non-target lesions: requires unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions" (NCT01121406)
Timeframe: From randomization until disease progression, death or study discontinuation; Up to 213 weeks
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | 13.1 |
| Cytotoxic | 20.6 |
t1/2; Terminal half-life of BI 6727 BS in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | hours (Geometric Mean) |
|---|---|
| Volasertib | 143 |
t1/2; Terminal half-life of CD 10899 BS in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | hours (Geometric Mean) |
|---|---|
| Volasertib | 146 |
"Time to deterioration in abdominal bloating/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.~The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death." (NCT01121406)
Timeframe: Every 6 weeks (Up to 213 weeks )
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | NA |
| Cytotoxic | 47.2 |
"Time to deterioration in fatigue/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.~The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death." (NCT01121406)
Timeframe: Every 6 weeks (Up to 213 weeks )
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | NA |
| Cytotoxic | 67.1 |
"Time to deterioration in global health status/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.~The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death." (NCT01121406)
Timeframe: Every 6 weeks (Up to 213 weeks )
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | NA |
| Cytotoxic | 39.6 |
"Time to deterioration in pain/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.~The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death." (NCT01121406)
Timeframe: Every 6 weeks (Up to 213 weeks )
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | NA |
| Cytotoxic | 54.1 |
"Three most troublesome disease specific symptoms, defined by the patient at baseline.~Patients that have defined more than 3 most troublesome symptoms have not been taken into account in the analysis.~Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.~The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death." (NCT01121406)
Timeframe: Every 6 weeks (Up to 213 weeks)
| Intervention | weeks (Median) |
|---|---|
| Volasertib (BI 6727) | NA |
| Cytotoxic | 18.9 |
tmax; time from dosing to maximum measured concentration of BI 6727 BS in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | hours (Median) |
|---|---|
| Volasertib | 2.00 |
tmax; time from dosing to maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | hours (Median) |
|---|---|
| Volasertib | 6.07 |
Vss;apparent volume of distribution at steady state following intravenous administration for BI 6727 BS (NCT01121406)
Timeframe: -0.083 hours (h), 2h, 4h, 6h, 24h, 168h and 336 h after first drug administration
| Intervention | Litres (Geometric Mean) |
|---|---|
| Volasertib | 5690 |
"Best overall response (BOR) is defined as the best response recorded at any time from the date of randomisation until the end of treatment.~Missing categories signify that no tumour imaging has been performed post baseline, and therefore the response status could not be assessed." (NCT01121406)
Timeframe: time from the date of randomisation until study completion/discontinuation; Up to 213 weeks
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| CR- Measurable disease | PR- Measurable disease | SD- Measurable disease | PD- Measurable disease | Missing- Measurable disease | CR- Non-measurable disease | Non-CR/Non-PD- Non-measurable disease | PD- Non-measurable disease | Missing- Non-measurable disease | |
| Cytotoxic | 0 | 8 | 24 | 10 | 2 | 1 | 9 | 0 | 1 |
| Volasertib (BI 6727) | 0 | 7 | 24 | 14 | 0 | 0 | 6 | 3 | 0 |
"Patients were to have a pre-treatment CA-125 of at least twice the upper limit of normal to be considered for CA-125 response. Patients were not evaluable by CA-125 if they had received mouse antibodies or if they had undergone medical and/or surgical interference with their peritoneum or pleura during the previous 28 days. In eligible patients, a CA-125 response was defined as the moment the CA- 25 was reduced by 50%, with this being confirmed with a consecutive CA-125 assessment not earlier than 28 days after the previous one.~Biological response rate based on serum CA-125 levels was assessed according to the guidelines by the Gynaecologic Cancer Intergroup. Monitoring of blood levels of the tumour marker CA-125 was performed at screening and every 6 weeks thereafter." (NCT01121406)
Timeframe: At screening and every 6 weeks thereafter (Up to 213 weeks)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Yes | No | Not evaluable | Missing | |
| Cytotoxic | 12 | 23 | 11 | 9 |
| Volasertib (BI 6727) | 10 | 33 | 4 | 7 |
Clinically relevant changes in laboratory and ECG data (NCT01121406)
Timeframe: From first treatment administration to 21 days after the last drug administration (Up to 1403 days)
| Intervention | percentage of participants (Number) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blood alkaline phosphatase increased | Blood creatinine increased | Platelet count decreased | Alanine aminotransferase increased | Aspartate aminotransferase increased | Blood uric acid increased | Gamma-glutamyltransferase increased | Alanine aminotransferase abnormal | Electrocardiogram QT prolonged | Haemoglobin decreased | Neutrophil count decreased | Troponin I increased | Blood lactate dehydrogenase increased | Blood magnesium decreased | White blood cell count decreased | Blood urea increased | Alanine aminotransferase decreased | Blood bilirubin increased | Blood creatine phosphokinase decreased | Blood potassium decreased | Hepatic enzyme increased | Aspartate aminotransferase abnormal | Transaminases increased | |
| Cytotoxic | 12.7 | 3.6 | 0.0 | 9.1 | 5.5 | 5.5 | 5.5 | 0.0 | 0.0 | 3.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.8 | 1.8 |
| Cytotoxic to Volasertib Switch | 8.3 | 0.0 | 8.3 | 4.2 | 4.2 | 0.0 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 | 4.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Volasertib (BI 6727) | 3.7 | 9.3 | 9.3 | 1.9 | 3.7 | 1.9 | 3.7 | 0.0 | 0.0 | 3.7 | 1.9 | 0.0 | 3.7 | 3.7 | 3.7 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 1.9 | 0.0 | 0.0 |
Incidence and intensity of adverse events according to the United States National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (NCT01121406)
Timeframe: From first treatment administration to 21 days after the last drug administration (Up to 1403 days)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Cytotoxic | 3 | 19 | 25 | 5 | 3 |
| Cytotoxic to Volasertib Switch | 1 | 3 | 9 | 6 | 3 |
| Volasertib (BI 6727) | 4 | 6 | 16 | 25 | 3 |
3 trials available for pteridines and Disease Exacerbation
| Article | Year |
|---|---|
Comprehensive Biomarker Analyses in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer Prospectively Treated with the Polo-Like Kinase 1 Inhibitor BI2536.
Topics: Antimitotic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progr | 2017 |
Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Cisplatin; Di | 2016 |
An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Cycle Proteins; Disease Progression; Dos | 2010 |
10 other studies available for pteridines and Disease Exacerbation
| Article | Year |
|---|---|
PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Dise | 2020 |
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferatio | 2015 |
Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Mov | 2016 |
TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases.
Topics: Animals; Base Sequence; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Disease Progressio | 2011 |
Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; D | 2012 |
In vitro PLK1 inhibition by BI 2536 decreases proliferation and induces cell-cycle arrest in melanoma cells.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2012 |
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Ce | 2012 |
Glioma-propagating cells as an in vitro screening platform: PLK1 as a case study.
Topics: Animals; Brain Neoplasms; Cell Cycle Proteins; Cell Proliferation; Cell Survival; Computational Biol | 2012 |
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Proliferation; Disease Progression; Epith | 2006 |
Juvenile form of dihydropteridine reductase deficiency in 2 Tunisian patients.
Topics: Adult; Age of Onset; Child; Consanguinity; Disease Progression; Follow-Up Studies; Humans; Male; Met | 1998 |